Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies

Tallantyre, Emma C. ORCID: https://orcid.org/0000-0002-3760-6634, Jacob, Emily, Davies, Laura, Loveless, Samantha ORCID: https://orcid.org/0000-0002-5124-4115, Carne, Emily, Bramhall, Kath, Schulze, Janika, Moat, Stuart J. and Jolles, Stephen 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal 31 (8) , pp. 1007-1010. 10.1177/13524585251330962

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (329kB) | Preview

Abstract

Anti-CD20 monoclonal antibodies are commonly used to manage neuroinflammatory diseases. The rate of B-cell re-emergence after dosing of ocrelizumab or rituximab varies considerably between individuals, but most people remain completely B-cell depleted at 6 months. Tailoring the dosing according to B-cell re-emergence may improve the safety profile of anti-CD20s but poses logistical challenges such as the need for regular attendances for whole-blood sampling. Here we combined a quantitative dried blood spot sampling technique with a DNA methylation test, to provide a reliable means of remotely monitoring B-cell counts, with 100% sensitivity and specificity for reaching >10 × 106 cells/L.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Sage
ISSN:	1352-4585
Funders:	N/A
Date of First Compliant Deposit:	3 April 2025
Date of Acceptance:	13 March 2025
Last Modified:	01 Oct 2025 15:00
URI:	https://orca.cardiff.ac.uk/id/eprint/177323

Actions (repository staff only)

Edit Item